Glucocorticoid-induced osteoporosis (GIOP) is the most common form of secondary osteoporosis and one of the most preventable. An estimated 30–50% of patients on long-term prednisone will develop it. A 2021 Canadian study (PMC8259736) found that only 15% of patients on glucocorticoids in Canadian rheumatology practices were receiving all the bone protection they should be. That's a serious gap — and most of those patients don't know they're in it.
Prednisone (and other glucocorticoids: methylprednisolone, hydrocortisone, dexamethasone, budesonide at high doses) is prescribed for dozens of conditions. The bone risk applies regardless of why you're taking it:
If you're on one of these medications and have never had a conversation about your bone density, that conversation is overdue. The DEXA scan process in Canada is straightforward — your GP can refer you, and it's covered by provincial health plans when there's a clinical indication.
Prednisone attacks bone through two simultaneous mechanisms, which is why it's so damaging. First, it directly suppresses osteoblast activity — the cells that build new bone. Second, it increases osteoclast-mediated bone resorption — the cells that break bone down. You get less building and more demolition at the same time.
Glucocorticoids also impair intestinal calcium absorption and increase urinary calcium loss, effectively starving bones of the mineral they need to maintain density. And they suppress the production of sex hormones (estrogen, testosterone), which normally help maintain bone mass.
The damage starts fast. Peak bone loss occurs in the first 3–6 months of glucocorticoid therapy — sometimes 5–15% of bone mass in that window alone. After that, the loss slows but continues as long as you're on steroids. This is not a slow insidious decline like postmenopausal osteoporosis; it's rapid and front-loaded.
Osteoporosis Canada's threshold: ≥5mg of prednisone per day (or equivalent) for ≥3 months triggers formal bone protection consideration. Higher doses accelerate the risk significantly. Even low doses (2.5–5mg/day) over years cause cumulative damage.
Inhaled corticosteroids at low-to-moderate doses are generally considered lower risk, but high-dose inhaled steroids — particularly in COPD management — have documented effects on bone density. If you're on fluticasone 500mcg/day or higher, or equivalent inhaled steroid doses, it's worth asking your respirologist about bone protection.
Important: fracture risk from glucocorticoids exceeds what T-score alone predicts. At the same T-score, a person on prednisone has a higher fracture risk than someone without glucocorticoid exposure. The FRAX calculator has a checkbox for glucocorticoid use precisely because of this — make sure it's checked if it applies to you.
The 2021 study published as PMC8259736 audited Canadian rheumatology practices specifically. Results: only 15% of patients on glucocorticoids were adhering to all Osteoporosis Canada guidelines for bone protection. This was across centres in British Columbia, Alberta, Ontario, and Quebec — it's not a regional problem.
The groups most likely to be undertreated: premenopausal women (often assumed to be too young for osteoporosis, even while on high-dose steroids), younger men, and patients from non-white backgrounds. If you fall into any of these groups and you're on glucocorticoids, you may need to advocate for yourself more actively.
Once you're on prednisone at the threshold dose (≥5mg/day for ≥3 months anticipated duration), Osteoporosis Canada recommends starting bone protection without waiting for a DEXA result. These interventions apply to essentially everyone on significant glucocorticoid therapy:
1,000–1,200mg of elemental calcium per day (from food plus supplements). This is the same target as the general adult recommendation. Given that glucocorticoids impair calcium absorption, getting enough calcium becomes more important, not less. See the calcium guide for how to assess your dietary intake and calculate what you need from supplements. Calcium carbonate is fine with food; calcium citrate is better absorbed and doesn't require food or stomach acid.
800–2,000 IU daily of vitamin D3. Health Canada recommends at least 600 IU for adults under 70 and 800 IU for those over 70, but Osteoporosis Canada's recommendation for patients with osteoporosis risk is higher. In Canada's northern latitude, most adults are insufficient especially in winter — see vitamin D in the Canadian winter for context. Patients on steroids should be at the higher end of the range.
Resistance training and weight-bearing aerobic exercise maintain bone density and muscle mass simultaneously — important because glucocorticoids also cause muscle wasting. Even modest exercise programs preserve BMD meaningfully. This doesn't require a gym: bodyweight squats, walking with a weighted backpack, and resistance bands are effective starting points. For evidence on what types of exercise work best for bone, see the exercise for bone density guide.
Glucocorticoids cause muscle weakness, which increases fall risk. Fall prevention is bone protection. The home fall prevention checklist covers practical modifications — grip bars, lighting, stair safety — that apply regardless of age.
Both independently accelerate bone loss. On top of glucocorticoid damage, they compound the risk substantially. Smoking cessation support is available through most provincial programs — in Ontario, the Smoke-Free Ontario program; in BC, QuitNow. Alcohol reduction to ≤2 drinks/day is the standard recommendation.
For many patients on glucocorticoids — particularly postmenopausal women and men over 50 — Osteoporosis Canada recommends starting a bisphosphonate at the same time as the steroid, without waiting for bone loss to occur. The threshold depends on your FRAX score adjusted for glucocorticoid use.
Alendronate (70mg weekly oral) or risedronate are the standard first-line choices. They're affordable, widely available as generics at Shoppers Drug Mart and Rexall, and covered on most provincial drug plans without special authorization for GIOP. For patients who can't tolerate oral bisphosphonates — gastrointestinal issues, swallowing problems, or poor compliance with the weekly regimen — IV zoledronic acid (Aclasta) is a reasonable alternative covered by most provincial plans.
The evidence for bisphosphonates in GIOP is strong. Alendronate significantly increases spine and hip BMD in glucocorticoid users and reduces vertebral fracture risk.
Premenopausal women are frequently undertreated because providers assume they're "too young" for osteoporosis medications. The evidence doesn't support this assumption when they're on significant glucocorticoids. Osteoporosis Canada guidelines explicitly address this: GIOP in younger women requires individualized assessment, and bisphosphonates are appropriate when fracture risk warrants it — even in women who might consider pregnancy. The teratogenicity concern with bisphosphonates in pregnancy is real but manageable with planning.
Prolia (denosumab) is sometimes used for GIOP when bisphosphonates aren't tolerated or effective. However, given the rebound fracture risk when stopping denosumab, this requires careful planning — especially in patients whose glucocorticoid therapy might eventually be tapered. Stopping the steroid doesn't mean the bone risk disappears immediately, and stopping Prolia simultaneously compounds the problem.
Bone protection should continue as long as glucocorticoid therapy continues. When the steroid is eventually tapered and stopped, bone density partially recovers — but recovery is often incomplete, especially if significant loss occurred early.
After discontinuing glucocorticoids, the approach shifts to standard osteoporosis management based on your current T-score and FRAX risk. A DEXA scan within a year of stopping steroids makes sense to establish a new baseline.
Do not stop your bone protection medication just because you've tapered your prednisone. The decision to stop bisphosphonates should be based on your current fracture risk — potentially including a structured drug holiday after 3–5 years if risk is low — not on the prednisone status alone.
Coverage is generally favourable for GIOP:
| Province | Generic Alendronate / Risedronate | IV Zoledronic Acid (Aclasta) | Prolia (for GIOP) |
|---|---|---|---|
| Ontario (ODB) | ✅ Covered | ✅ With criteria | ✅ With special authorization |
| British Columbia (BC PharmaCare) | ✅ Covered | ✅ With special authority | ✅ With special authority |
| Alberta (Drug Benefit List) | ✅ Covered | ✅ With criteria | ✅ With special authorization |
| Quebec (RAMQ) | ✅ Covered | ✅ With criteria | ✅ With exceptional access |
| Saskatchewan / Manitoba | ✅ Covered | ✅ With criteria | ⚠️ Varies |
Generic alendronate — roughly $10–$25/month at any major pharmacy — is the practical first choice for most patients. If your provincial plan requires criteria to be met for bisphosphonate coverage in GIOP, your rheumatologist or prescribing specialist can usually provide the necessary documentation.
If you've been on prednisone (or equivalent) for more than 3 months at ≥5mg/day and no one has mentioned bone health, ask directly: "Given my steroid dose and duration, should I have a bone density test, and should I be on a bisphosphonate?"
The answer should include a DEXA scan if you haven't had one, calcium and vitamin D dosing guidance, and a discussion of whether bisphosphonate therapy is appropriate. If the response is vague, a referral to an endocrinologist or a bone health specialist at a metabolic bone clinic is reasonable to request.